<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974216</url>
  </required_header>
  <id_info>
    <org_study_id>VERLen</org_study_id>
    <nct_id>NCT04974216</nct_id>
  </id_info>
  <brief_title>Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older</brief_title>
  <official_title>Phase II, Open-Label Study Evaluating Efficacy of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the efficacy of Tafasitamab and Lenalinomide associated to Rituximab in&#xD;
      elderly patients with frontline Diffuse Large B-Cell Lymphoma as assessed by the Overall&#xD;
      Response Rate (ORR) after 3 cycles of treatment according to Lugano Response Criteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label, multi-centric, phase II study designed to evaluate the efficacy&#xD;
      of Tafasitamab and Lenalinomide associated to Rituximab in elderly patients with frontline&#xD;
      Diffuse Large B-Cell Lymphoma as assessed by the Overall Response Rate (ORR) after 3 cycles&#xD;
      of treatment according to Lugano Response Criteria.&#xD;
&#xD;
      After a screening phase, eligible patients will be enrolled and start the prephase treatment&#xD;
      with vincristine and prednisone before day 1 of cycle 1 of the experimental drugs.&#xD;
&#xD;
      Patients with Progressive Disease or Stable Disease after 3 cycles should start a&#xD;
      conventional chemotherapy (R-miniCHOP) at Investigator's discretion and will remain in the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) by local assessment</measure>
    <time_frame>3 months (3 cycles of 28 days)</time_frame>
    <description>LOCAL ASSESSMENT : Complete Metabolic Response + Partial Metabolic Response based according to Lugano Response Criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events (SAE) of patients treated with lenalidomide and tafasitamab</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of SAE of patients who switched to RminiCHOP</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) by central assessment</measure>
    <time_frame>3 months (3 cycles of 28 days)</time_frame>
    <description>CENTRAL ASSESSMENT : Complete Metabolic Response + Partial Metabolic Response based according to Lugano Response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Metabolic Response (CMR) by local assessment</measure>
    <time_frame>3 months (3 cycles of 28 days)</time_frame>
    <description>LOCAL ASSESSMENT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Metabolic Response (CMR) by central assessment</measure>
    <time_frame>3 months (3 cycles of 28 days)</time_frame>
    <description>CENTRAL ASSESSMENT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Metabolic Response (CMR) by local assessment</measure>
    <time_frame>6 months (6 cycles of 28 days)</time_frame>
    <description>LOCAL ASSESSMENT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Metabolic Response (CMR) by central assessment</measure>
    <time_frame>6 months (6 cycles of 28 days)</time_frame>
    <description>CENTRAL ASSESSMENT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Metabolic Response (CMR) by local assessment</measure>
    <time_frame>12 months (12 cycles of 28 days = end of treatment)</time_frame>
    <description>LOCAL ASSESSMENT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Metabolic Response (CMR) by central assessment</measure>
    <time_frame>12 months (12 cycles of 28 days = end of treatment)</time_frame>
    <description>CENTRAL ASSESSMENT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) by local assessment</measure>
    <time_frame>6 months (6 cycles of 28 days)</time_frame>
    <description>LOCAL ASSESSMENT : Complete Metabolic Response + Partial Metabolic Response based according to Lugano Response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) by central assessment</measure>
    <time_frame>6 months (6 cycles of 28 days)</time_frame>
    <description>CENTRAL ASSESSMENT : Complete Metabolic Response + Partial Metabolic Response based according to Lugano Response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) by local assessment</measure>
    <time_frame>12 months (12 cycles of 28 days = end of treatment)</time_frame>
    <description>LOCAL ASSESSMENT : Complete Metabolic Response + Partial Metabolic Response based according to Lugano Response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) by central assessment</measure>
    <time_frame>12 months (12 cycles of 28 days = end of treatment)</time_frame>
    <description>CENTRAL ASSESSMENT : Complete Metabolic Response + Partial Metabolic Response based according to Lugano Response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) of patients who switched to RminiCHOP</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) of patients who switched to RminiCHOP</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">71</enrollment>
  <condition>DLBCL</condition>
  <arm_group>
    <arm_group_label>R-Lena-Tafa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 cycles of 28 days. From C1 to C6 : rituximab + tafasitamab + lenalidomide and from C7 to C12: tafasitamab and lenalidomide&#xD;
Patients with Progressive Disease or Stable Disease after 3 cycles should start a conventional chemotherapy (rituximab + cyclophosphamide + adriamycine + vincristine + prednisone R-miniCHOP) at Investigator's discretion according to local practices</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafasitamab</intervention_name>
    <description>Administration : IV at 12mg/Kg C1 to C3: D1, D8, D15, D22 C4 to C6: D1, D15 C7 to C12: D1</description>
    <arm_group_label>R-Lena-Tafa</arm_group_label>
    <other_name>MOR208</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Oral administration: hard capsule C1 to C6: 20mg/day C7 to C12: 15mg/day</description>
    <arm_group_label>R-Lena-Tafa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Administration: IV at 375mg/m2 C1 to C6: D1</description>
    <arm_group_label>R-Lena-Tafa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        2.Patient with histologically proven CD20+ diffuse large B-cell lymphoma (DLBCL) (WHO&#xD;
        classification 2017) including all clinical subtypes (primary mediastinal, intravascular,&#xD;
        etc…), with all International Prognostic Index (IPI). May also be enrolled the following&#xD;
        malignancies:&#xD;
&#xD;
          -  De Novo transformed DLBCL from low grade lymphoma (Follicular, other...) and DLBCL&#xD;
             associated with some small cell infiltration in bone marrow or lymph node.&#xD;
&#xD;
          -  High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements&#xD;
&#xD;
          -  High-grade B-cell lymphoma, Not Otherwise Specified (NOS)&#xD;
&#xD;
          -  Follicular lymphoma grade 3B 3.Positron-Emission Tomography (PET)-positive disease&#xD;
             4.Previously untreated high-grade B-cell lymphoma 5.Aged ≥ 80 years old at the time of&#xD;
             signing the informed consent form (ICF) 6.Ann Arbor stage I, II, III or IV 7.Eastern&#xD;
             Cooperative Oncology Group (ECO)G performance status ≤ 2 8.With a minimum life&#xD;
             expectancy of 3 months 9.Male patients must practice complete abstinence or agree to&#xD;
             use a condom during sexual contact with a pregnant female or a female of childbearing&#xD;
             potential while participating in the study, during dose interruptions, and for 4&#xD;
             months following study drug discontinuation, even if they have undergone a successful&#xD;
             vasectomy 10. Patients should be able to receive R-miniCHOP regimen (left ventricular&#xD;
             ejection fraction &gt; 50% and good general condition, according to investigator's&#xD;
             judgment) 11. Patients should be able to receive adequate prophylaxis and/or therapy&#xD;
             for thromboembolic events (aspirin or low molecular weight heparin) 12. Patient&#xD;
             covered by any social security system (France)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other histological type of lymphoma, Burkitt included&#xD;
&#xD;
          2. Any history of treated or non-treated Small-B cell lymphoma prior Aggressive B Cell&#xD;
             lymphoma diagnosis&#xD;
&#xD;
          3. Central nervous system or meningeal involvement by lymphoma&#xD;
&#xD;
          4. Any serious active disease (according to the investigator's decision)&#xD;
&#xD;
          5. Poor renal function (calculated Cockcroft-Gault creatinine clearance &lt; 30 ml/min)&#xD;
&#xD;
          6. Poor hepatic function (total bilirubin level &gt;30 μmol/l, transaminases &gt;2.5 upper&#xD;
             normal limits) unless these abnormalities are related to lymphoma&#xD;
&#xD;
          7. Poor bone marrow reserve as defined by neutrophils &lt;1.5 G/l or platelets &lt;100 G/l,&#xD;
             unless related to bone marrow infiltration by lymphoma cells (Bone Marrow Aspiration&#xD;
             will be mandatory in case of severe cytopenias prior inclusion)&#xD;
&#xD;
          8. Any history of cancer during the last 5 years with the exception of non-melanoma skin&#xD;
             tumors or stage 0 (in situ) cervical carcinoma. Patients previously diagnosed with&#xD;
             prostate cancer are eligible if (1) their disease was T1-T2a, N0, M0, with a Gleason&#xD;
             score ≤7, and a prostate specific antigen (PSA) ≤10 ng/mL prior to initial therapy,&#xD;
             (2) they had definitive curative therapy (i.e., prostatectomy or radiotherapy) 2 years&#xD;
             before Day 1 of Cycle 1, and (3) at a minimum 2 years following therapy they had no&#xD;
             clinical evidence of prostate cancer, and their PSA was undetectable if they underwent&#xD;
             prostatectomy or &lt;1 ng/mL if they did not undergo prostatectomy&#xD;
&#xD;
          9. Treatment with any investigational drug within 30 days prior to prephase treatment and&#xD;
             during the study&#xD;
&#xD;
         10. Known HIV, active Hepatitis C Virus (HCV) infection or positive Hepatitis B Virus&#xD;
             (HBV) test within 4 weeks before enrollment (except after hepatitis B vaccination or&#xD;
             for patients who are HBs Ag negative, anti-HBs positive and/or anti-HBc positive but&#xD;
             viral DNA negative)&#xD;
&#xD;
         11. Prior treatment with anti-CD20/anti-CD19 monoclonal antibody or alemtuzumab within 3&#xD;
             months prior to prephase treatment&#xD;
&#xD;
         12. Prior ≥ Grade 3 allergic reaction/hypersensitivity to thalidomide&#xD;
&#xD;
         13. Contra-indication to highly dosed glucocorticoid (60 mg/m2/d)&#xD;
&#xD;
         14. Neuropathy ≥ Grade 2 or painful&#xD;
&#xD;
         15. Patient deprived of his/her liberty by a judicial or administrative decision&#xD;
&#xD;
         16. Adult patient under legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinique Universitaire Saint LUC</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Sarah Bailly, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires de Bruxelles - Hôpital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie MAEROVOET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Mont Godinne</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc ANDRE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Haut Lévêque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>François-Xavier GROS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié - Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anna SCHMITT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Saint Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>AMORIM Sandy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de LILLE - Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Franck MORSHHAUSER, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Limoges - Hopital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Julie ABRAHAM, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Steven LE GOUILL, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fréderic PEYRADE, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine THIEBLEMONT, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabrice JARDIN, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin - Institut Curie</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sandra MALAK, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Ludovic FOUILLET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre FEUGIER, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

